Isomorphic Labs develops a unified AI drug design engine (IsoDDE) composed of proprietary foundational AI models intended to work across multiple therapeutic areas and drug modalities. The company says IsoDDE provides predictive fidelity that bridges structure prediction and real-world drug discovery and has already demonstrated progress across internal programs. Isomorphic Labs advances a portfolio of partnered programs and wholly-owned internal programs, and maintains strategic collaborations with Novartis, Lilly, and Johnson & Johnson. Following a $2.1 billion Series B, the company plans to scale its technology globally, expand its pipeline toward clinical candidates, and hire AI, engineering, drug design, and clinical talent. Founded in 2021, Isomorphic Labs is headquartered in London and has offices in Cambridge, Massachusetts and Lausanne, Switzerland.

Total raised

$2.7B

Funding rounds

2

Latest round

Series B

Latest activity

May 2026